Modality
Vaccine
MOA
PCSK9i
Target
CD3
Pathway
Complement
WMPSPRSV
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
Jan 2018
→ Feb 2031
Phase 3Current
NCT08657490
708 pts·PSP
2018-01→2031-02·Terminated
NCT05535908
2,394 pts·PSP
2023-08→2029-12·Active
NCT07541281
1,705 pts·RSV
2020-05→2027-02·Not yet recruiting
+1 more trial
5,287 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-04-081w awayPh3 Readout· WM
2027-02-2311mo awayPh3 Readout· RSV
2029-12-023.7y awayPh3 Readout· PSP
2031-02-014.8y awayPh3 Readout· PSP
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Termina…
P3
Not yet…
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2026-04-08 · 1w away
WM
Ph3 Readout
2027-02-23 · 11mo away
RSV
Ph3 Readout
2029-12-02 · 3.7y away
PSP
Ph3 Readout
2031-02-01 · 4.8y away
PSP
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08657490 | Phase 3 | PSP | Terminated | 708 | SeizFreq |
| NCT05535908 | Phase 3 | PSP | Active | 2394 | VA |
| NCT07541281 | Phase 3 | RSV | Not yet recr... | 1705 | DAS28 |
| NCT03176451 | Phase 3 | WM | Not yet recr... | 480 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |